Secreted Protein Acidic and Rich in Cysteine (SPARC) Induces Epithelial-mesenchymal Transition, Enhancing Migration and Invasion, and is Associated with High Gleason Score in Prostate Cancer

Overview

Journal Asian J Androl

Specialty Urology

Date 2019 Apr 30

PMID 31031331

Citations 9

Authors

Fernanda Lopez-Moncada

Maria Jose Torres

Enrique A Castellon

Hector R Contreras

Affiliations

Soon will be listed here.

Abstract

Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein highly expressed in bone tissue that acts as a chemoattractant factor promoting the arrival of prostate cancer (PCa) cells to the bone marrow. However, the contribution of SPARC during the early stages of tumor progression remains unclear. In this study, we show that SPARC is highly expressed in PCa tissues with a higher Gleason score. Through stable knockdown and overexpression of SPARC in PC3 and LNCaP cells, respectively, here we demonstrate that endogenous SPARC induces the epithelial-mesenchymal transition (EMT), decreasing E-cadherin and cytokeratin 18 and increasing N-cadherin and vimentin. Moreover, SPARC induces the expression of EMT regulatory transcription factors Snail family transcriptional repressor 1 (Snail), Snail family transcriptional repressor 2 (Slug), and zinc finger E-box binding homeobox 1 (Zeb1). In addition, SPARC knockdown in PC3 cells decreases migration and invasion in vitro, without modifying cell proliferation. Our results indicate that SPARC might facilitate tumor progression by modifying the cellular phenotype in cancer cells.

Citing Articles

Novel transcripts of EMT driving the malignant transformation of oral submucous fibrosis.

Shetty S, Padam K, Sharma M, Kudva A, Patel P, Radhakrishnan R Sci Rep. 2025; 15(1):3294.

PMID: 39865173 PMC: 11770107. DOI: 10.1038/s41598-025-87790-2.

The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery.

Samarzija I Biomedicines. 2024; 12(1).

PMID: 38255186 PMC: 10813710. DOI: 10.3390/biomedicines12010079.

TGF-β1 upregulates secreted protein acidic and rich in cysteine expression in human granulosa-lutein cells: a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome.

Dang X, Fang L, Jia Q, Wu Z, Guo Y, Liu B Cell Commun Signal. 2023; 21(1):101.

PMID: 37158892 PMC: 10165787. DOI: 10.1186/s12964-023-01123-2.

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation.

Natkin R, Pennanen P, Syvala H, Blauer M, Kesseli J, Tammela T PLoS One. 2023; 18(2):e0281645.

PMID: 36809527 PMC: 9942993. DOI: 10.1371/journal.pone.0281645.

SPARC Induces E-Cadherin Repression and Enhances Cell Migration through Integrin αvβ3 and the Transcription Factor ZEB1 in Prostate Cancer Cells.

Lopez-Moncada F, Torres M, Lavanderos B, Cerda O, Castellon E, Contreras H Int J Mol Sci. 2022; 23(11).

PMID: 35682554 PMC: 9180154. DOI: 10.3390/ijms23115874.

References

Nagaraju G, Dontula R, El-Rayes B, Lakka S . Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. Carcinogenesis. 2014; 35(5):967-73. DOI: 10.1093/carcin/bgu072. View

Farfan N, Ocarez N, Castellon E, Mejia N, Garcia de Herreros A, Contreras H . The transcriptional factor ZEB1 represses Syndecan 1 expression in prostate cancer. Sci Rep. 2018; 8(1):11467. PMC: 6068163. DOI: 10.1038/s41598-018-29829-1. View

Grant J, Fishbein M, Hong L, Krysan K, Minna J, Shay J . A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis. Cancer Prev Res (Phila). 2013; 7(1):150-60. PMC: 3919444. DOI: 10.1158/1940-6207.CAPR-13-0263. View

Arnold S, Brekken R . SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal. 2009; 3(3-4):255-73. PMC: 2778590. DOI: 10.1007/s12079-009-0072-4. View

Chang C, Yen M, Liao S, Hsu Y, Lai C, Chang K . Secreted Protein Acidic and Rich in Cysteine (SPARC) Enhances Cell Proliferation, Migration, and Epithelial Mesenchymal Transition, and SPARC Expression is Associated with Tumor Grade in Head and Neck Cancer. Int J Mol Sci. 2017; 18(7). PMC: 5536044. DOI: 10.3390/ijms18071556. View

Vega S, Morales A, Ocana O, Valdes F, Fabregat I, Nieto M . Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004; 18(10):1131-43. PMC: 415638. DOI: 10.1101/gad.294104. View

Sartor O, de Bono J . Metastatic Prostate Cancer. N Engl J Med. 2018; 378(7):645-657. DOI: 10.1056/NEJMra1701695. View

Zhang P, Wei Y, Wang L, Debeb B, Yuan Y, Zhang J . ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014; 16(9):864-75. PMC: 4150825. DOI: 10.1038/ncb3013. View

Jiang H, Li T, Qu Y, Wang X, Li B, Song J . Long non-coding RNA SNHG15 interacts with and stabilizes transcription factor Slug and promotes colon cancer progression. Cancer Lett. 2018; 425:78-87. DOI: 10.1016/j.canlet.2018.03.038. View

10.

Chen N, Ye X, Chu K, Navone N, Sage E, Yu-Lee L . A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 2007; 67(14):6544-8. PMC: 2000837. DOI: 10.1158/0008-5472.CAN-07-1330. View

11.

Liu J, Uygur B, Zhang Z, Shao L, Romero D, Vary C . Slug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression. Prostate. 2010; 70(16):1768-77. PMC: 2943978. DOI: 10.1002/pros.21213. View

12.

Sung S, Chang J, Chen K, Yeh S, Liu Y, Su Y . Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth. PLoS One. 2016; 11(4):e0153350. PMC: 4824507. DOI: 10.1371/journal.pone.0153350. View

13.

Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo J . The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One. 2012; 7(7):e40378. PMC: 3401237. DOI: 10.1371/journal.pone.0040378. View

14.

Tai I, Tang M . SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008; 11(6):231-46. DOI: 10.1016/j.drup.2008.08.005. View

15.

Said N, Frierson Jr H, Chernauskas D, Conaway M, Motamed K, Theodorescu D . The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene. 2009; 28(39):3487-98. DOI: 10.1038/onc.2009.205. View

16.

Kapinas K, Lowther K, Kessler C, Tilbury K, Lieberman J, Tirnauer J . Bone matrix osteonectin limits prostate cancer cell growth and survival. Matrix Biol. 2012; 31(5):299-307. PMC: 3367100. DOI: 10.1016/j.matbio.2012.03.002. View

17.

Chong H, Tan C, Huang R, Tan N . Matricellular proteins: a sticky affair with cancers. J Oncol. 2012; 2012:351089. PMC: 3306981. DOI: 10.1155/2012/351089. View

18.

Hung J, Yen M, Jian S, Wu C, Chang W, Liu K . Secreted protein acidic and rich in cysteine (SPARC) induces cell migration and epithelial mesenchymal transition through WNK1/snail in non-small cell lung cancer. Oncotarget. 2017; 8(38):63691-63702. PMC: 5609953. DOI: 10.18632/oncotarget.19475. View

19.

Robichaud N, Del Rincon S, Huor B, Alain T, Petruccelli L, Hearnden J . Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene. 2014; 34(16):2032-42. PMC: 4978545. DOI: 10.1038/onc.2014.146. View

20.

Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M . EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci. 2012; 69(20):3429-56. PMC: 11115078. DOI: 10.1007/s00018-012-1122-2. View